trial

A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia

NCTId NCT01615185
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 96 (actual)
Sponsored by Kaohsiung Kai-Suan Psychiatric Hospital
Primary completion 2011-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
96 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-01
Primary completion
2011-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Amisulpride

Sponsors

Kaohsiung Kai-Suan Psychiatric HospitalLead Sponsor

Investigators

1
Ching-Hua Lin, MD, PhDPrincipal Investigator

Sites

1 total
Kaohsiung City, Taiwan

Facts & assertions

4 sourced
Enrollment
96
Phase
PHASE4
Primary Completion Date
2011-12
Status
TERMINATED
relationships
The graph out of here
drug
Amisulpride
drug
lead_sponsor
Kaohsiung Kai-Suan Psychiatric Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Ching-Hua Lin, MD, PhD
person